These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511 [TBL] [Abstract][Full Text] [Related]
5. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Calabrò L; Morra A; Fonsatti E; Cutaia O; Fazio C; Annesi D; Lenoci M; Amato G; Danielli R; Altomonte M; Giannarelli D; Di Giacomo AM; Maio M Lancet Respir Med; 2015 Apr; 3(4):301-9. PubMed ID: 25819643 [TBL] [Abstract][Full Text] [Related]